Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track JAGX with free AI briefings, catalyst countdowns, and dilution alerts.

JAGX · Jaguar Health, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$5.5M Cash on Hand
3.2mo Cash Runway
Follow JAGX by email Get an email when JAGX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about JAGX, unsubscribe in one click. Privacy

📣 What JAGX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

💰 Cash Runway & Dilution Risk

JAGX holds $5.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $5.1M/quarter from operations, an estimated runway of 3.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 30 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when JAGX files for a raise →

👥 Who Owns JAGX

Insiders 0.4% Other 5%+ holders 0.4% Institutions (9 holders) 0.4% Public and other holders 98.8%
HolderTypeShares% of sharesAs of
Lincoln Alternative Strategies LLC
10% owner
Insider 600,000 0.35% 2025-08-28
Iliad Research & Trading, L.P. 5%+ holder (13G) 440,000 0.26% 2025-12-11
Joshua Mailman 5%+ holder (13G) 189,617 0.11% 2026-09-12
Lisa A Conte
Chief Exec. Officer & President, Directo · +188,074 options
Insider 29,258 0.02% 2025-12-11
Jonathan S. Wolin
Chief of Staff, Chief Compliance Officer · +79,449 options
Insider 11,938 0.01% 2025-12-11
Pravin R Chaturvedi
Chief Scientific Officer · +66,572 options
Insider 11,938 0.01% 2025-12-11
Carol R. Lizak
Chief Financial Officer · +57,211 options
Insider 11,911 0.01% 2025-12-11
Steven R. King
Officer · +62,101 options
Insider 11,885 0.01% 2025-12-11
John Micek
Director · +61,339 options
Insider 7,430 0.00% 2025-12-11
Jonathan B. Siegel
Director · +70,339 options
Insider 7,423 0.00% 2025-12-11
James J Bochnowski
Director · +111,955 options
Insider 6,415 0.00% 2025-12-11
Anula Jayasuriya
Director · +26,870 options
Insider 5,916 0.00% 2025-12-11

Share count 171,350,166 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full JAGX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JAGX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.